350 related articles for article (PubMed ID: 34268304)
21. 5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer.
Wang K; Zhong W; Long Z; Guo Y; Zhong C; Yang T; Wang S; Lai H; Lu J; Zheng P; Mao X
Front Mol Biosci; 2021; 8():775304. PubMed ID: 34926580
[TBL] [Abstract][Full Text] [Related]
22. Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma.
Lu J; Wang H; Cao W; Chen D; He Z; Xu J
Hum Cell; 2023 Mar; 36(2):712-724. PubMed ID: 36520346
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
24. Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma.
Lu L; Liu LP; Zhao QQ; Gui R; Zhao QY
Front Oncol; 2021; 11():675545. PubMed ID: 34249715
[TBL] [Abstract][Full Text] [Related]
25. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
[TBL] [Abstract][Full Text] [Related]
26. Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma.
Zhao J; Li G; Zhao G; Wang W; Shen Z; Yang Y; Huang Y; Ye L
Front Oncol; 2022; 12():986367. PubMed ID: 36387240
[TBL] [Abstract][Full Text] [Related]
27. Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma.
Wu G; Wang Q; Zhu T; Fu L; Li Z; Wu Y; Zhang C
Front Genet; 2021; 12():681277. PubMed ID: 34306024
[TBL] [Abstract][Full Text] [Related]
28. Identification of Tumor Microenvironment-Related Prognostic lncRNAs in Lung Adenocarcinoma.
Yuan L; Li F; Wang S; Yi H; Li F; Mao Y
Front Oncol; 2021; 11():719812. PubMed ID: 34408984
[TBL] [Abstract][Full Text] [Related]
29. Autophagy-related long non-coding RNA prognostic model predicts prognosis and survival of melanoma patients.
Qiu Y; Wang HT; Zheng XF; Huang X; Meng JZ; Huang JP; Wen ZP; Yao J
World J Clin Cases; 2022 Apr; 10(11):3334-3351. PubMed ID: 35611195
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of stemness-related lncRNA prognostic signature for breast cancer.
Li X; Li Y; Yu X; Jin F
J Transl Med; 2020 Aug; 18(1):331. PubMed ID: 32867770
[TBL] [Abstract][Full Text] [Related]
31. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
[TBL] [Abstract][Full Text] [Related]
32. 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas.
Zhang J; Wang N; Wu J; Gao X; Zhao H; Liu Z; Yan X; Dong J; Wang F; Ba Y; Ma S; Jin J; Du J; Ji H; Hu S
Front Immunol; 2022; 13():844778. PubMed ID: 35309316
[TBL] [Abstract][Full Text] [Related]
33. A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients With Lung Adenocarcinoma.
Tu G; Peng W; Cai Q; Zhao Z; Peng X; He B; Zhang P; Shi S; Wang X
Front Genet; 2021; 12():720013. PubMed ID: 34777461
[No Abstract] [Full Text] [Related]
34. Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer.
Huang Z; Pan J; Wang H; Du X; Xu Y; Wang Z; Chen D
Front Cell Dev Biol; 2021; 9():657547. PubMed ID: 33928086
[TBL] [Abstract][Full Text] [Related]
35. 5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.
Li Z; Wang S; Chen Y; Huang Y; Li T
Dis Markers; 2022; 2022():3117359. PubMed ID: 35371346
[TBL] [Abstract][Full Text] [Related]
36. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
Li Y; Li X; Yu Z
Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
[TBL] [Abstract][Full Text] [Related]
37. A five-long non-coding RNA signature with the ability to predict overall survival of patients with lung adenocarcinoma.
Zeng L; Wang W; Chen Y; Lv X; Yuan J; Sun R; Yang S
Exp Ther Med; 2019 Dec; 18(6):4852-4864. PubMed ID: 31777562
[TBL] [Abstract][Full Text] [Related]
38. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
39. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
Front Genet; 2022; 13():903117. PubMed ID: 35692827
[No Abstract] [Full Text] [Related]
40. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.
Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z
Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]